184 related articles for article (PubMed ID: 38159110)
1. Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models.
Pusch FF; Dorado García H; Xu R; Gürgen D; Bei Y; Brückner L; Röefzaad C; von Stebut J; Bardinet V; Chamorro Gonzalez R; Eggert A; Schulte JH; Hundsdörfer P; Seifert G; Haase K; Schäfer BW; Wachtel M; Kühl AA; Ortiz MV; Wengner AM; Scheer M; Henssen AG
Mol Cancer Ther; 2024 Apr; 23(4):507-519. PubMed ID: 38159110
[TBL] [Abstract][Full Text] [Related]
2. Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor.
Manavella DD; McNamara B; Harold J; Bellone S; Hartwich TMP; Yang-Hartwich Y; Mutlu L; Zipponi M; Demirkiran C; Verzosa MS; Altwerger G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Dottino PR; Choi J; Alexandrov LB; Buza N; Hui P; Santin AD
Gynecol Oncol; 2023 Feb; 169():98-105. PubMed ID: 36525930
[TBL] [Abstract][Full Text] [Related]
3. Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.
Lowery CD; Dowless M; Renschler M; Blosser W; VanWye AB; Stephens JR; Iversen PW; Lin AB; Beckmann RP; Krytska K; Cole KA; Maris JM; Hawkins DS; Rubin BP; Kurmasheva RT; Houghton PJ; Gorlick R; Kolb EA; Kang MH; Reynolds CP; Erickson SW; Teicher BA; Smith MA; Stancato LF
Clin Cancer Res; 2019 Apr; 25(7):2278-2289. PubMed ID: 30563935
[TBL] [Abstract][Full Text] [Related]
4. The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
Sartori G; Tarantelli C; Spriano F; Gaudio E; Cascione L; Mascia M; Barreca M; Arribas AJ; Licenziato L; Golino G; Ferragamo A; Pileri S; Damia G; Zucca E; Stathis A; Politz O; Wengner AM; Bertoni F
Br J Haematol; 2024 Jan; 204(1):191-205. PubMed ID: 38011941
[TBL] [Abstract][Full Text] [Related]
5. Nuclear pCHK1 as a potential biomarker of increased sensitivity to ATR inhibition.
Sundararajan V; Tan TZ; Lim D; Peng Y; Wengner AM; Ngoi NYL; Jeyasekharan AD; Tan DSP
J Pathol; 2023 Feb; 259(2):194-204. PubMed ID: 36373784
[TBL] [Abstract][Full Text] [Related]
6. Quantitation of the ataxia-telangiectasia-mutated and Rad3-related inhibitor elimusertib (BAY-1895344) in human plasma using LC-MS/MS.
Kiesel BF; Parise RA; Krishnamurthy A; Gore S; Beumer JH
Biomed Chromatogr; 2022 Nov; 36(11):e5455. PubMed ID: 35876841
[TBL] [Abstract][Full Text] [Related]
7. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.
Harold J; Bellone S; Manavella DD; Mutlu L; McNamara B; Hartwich TMP; Zipponi M; Yang-Hartwich Y; Demirkiran C; Verzosa MS; Choi J; Dong W; Buza N; Hui P; Altwerger G; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2023 Jan; 168():157-165. PubMed ID: 36442427
[TBL] [Abstract][Full Text] [Related]
8. The suppression of ATR/Chk1 pathway by Elimusertib ATR inhibitor in triple negative breast cancer cells.
Haciefendi A; Guney Eskiler G
Am J Transl Res; 2023; 15(7):4902-4911. PubMed ID: 37560219
[TBL] [Abstract][Full Text] [Related]
9. Preclinical validation of a novel therapeutic strategy for choroid plexus carcinoma.
Martin B; Garman T; Laramee M; Wang A; Zhang X; Beck E; Wilson K; Klumpp-Thomas C; McKnight C; Xu X; Hagen N; Holland D; Dahmane N; Thomas CJ; Souweidane M
J Control Release; 2023 May; 357():580-590. PubMed ID: 37054779
[TBL] [Abstract][Full Text] [Related]
10. Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.
Gorlick R; Maris JM; Houghton PJ; Lock R; Carol H; Kurmasheva RT; Kolb EA; Keir ST; Reynolds CP; Kang MH; Billups CA; Smith MA
Pediatr Blood Cancer; 2012 Sep; 59(3):518-24. PubMed ID: 22102563
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the treatment strategies on patient-derived xenograft mice of human breast tumor.
Khalighfard S; Alizadeh AM; Poorkhani A; Motahari M; Tahmasebifar A; Omranipour R; Keshavarz P; Haddad P
Eur J Pharmacol; 2020 Dec; 889():173605. PubMed ID: 32980347
[TBL] [Abstract][Full Text] [Related]
12. ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
Wilson Z; Odedra R; Wallez Y; Wijnhoven PWG; Hughes AM; Gerrard J; Jones GN; Bargh-Dawson H; Brown E; Young LA; O'Connor MJ; Lau A
Cancer Res; 2022 Mar; 82(6):1140-1152. PubMed ID: 35078817
[TBL] [Abstract][Full Text] [Related]
13. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
[TBL] [Abstract][Full Text] [Related]
14. Systematic Review of Patient-Derived Xenograft Models for Preclinical Studies of Anti-Cancer Drugs in Solid Tumors.
Koga Y; Ochiai A
Cells; 2019 May; 8(5):. PubMed ID: 31064068
[TBL] [Abstract][Full Text] [Related]
15. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.
Maris JM; Courtright J; Houghton PJ; Morton CL; Gorlick R; Kolb EA; Lock R; Tajbakhsh M; Reynolds CP; Keir ST; Wu J; Smith MA
Pediatr Blood Cancer; 2008 Mar; 50(3):581-7. PubMed ID: 17457854
[TBL] [Abstract][Full Text] [Related]
16. Targeting ATR in Cancer Medicine.
Salguero C; Valladolid C; Robinson HMR; Smith GCM; Yap TA
Cancer Treat Res; 2023; 186():239-283. PubMed ID: 37978140
[TBL] [Abstract][Full Text] [Related]
17. Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models.
Niwa Y; Asano M; Nakagawa T; France D; Semba T; Funahashi Y
Anticancer Res; 2020 Dec; 40(12):6699-6712. PubMed ID: 33288563
[TBL] [Abstract][Full Text] [Related]
18. Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.
Hatem R; Labiod D; Château-Joubert S; de Plater L; El Botty R; Vacher S; Bonin F; Servely JL; Dieras V; Bièche I; Marangoni E
Int J Cancer; 2016 May; 138(10):2510-21. PubMed ID: 26686064
[TBL] [Abstract][Full Text] [Related]
19. Patient-derived xenografts for childhood solid tumors: a valuable tool to test new drugs and personalize treatments.
Zarzosa P; Navarro N; Giralt I; Molist C; Almazán-Moga A; Vidal I; Soriano A; Segura MF; Hladun R; Villanueva A; Gallego S; Roma J
Clin Transl Oncol; 2017 Jan; 19(1):44-50. PubMed ID: 27718156
[TBL] [Abstract][Full Text] [Related]
20. The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models.
Kendsersky NM; Lindsay J; Kolb EA; Smith MA; Teicher BA; Erickson SW; Earley EJ; Mosse YP; Martinez D; Pogoriler J; Krytska K; Patel K; Groff D; Tsang M; Ghilu S; Wang Y; Seaman S; Feng Y; Croix BS; Gorlick R; Kurmasheva R; Houghton PJ; Maris JM
Clin Cancer Res; 2021 May; 27(10):2938-2946. PubMed ID: 33619171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
